The BioHub - by Avetix

Afleveringen

1. Episode 256 - Sean Ekins - Collaborations Pharmaceuticals

   4 november 2026 · 30 min

   Afspelen
   In this episode of The BioHub, Amber is joined by Dr. Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals. Lees meer

   Sean shares his perspective on the evolving role of machine learning in drug discovery, how computational approaches can support rare and neglected disease research, and what it really takes to move from prediction to meaningful therapeutic development.

   They also discuss the opportunities and limitations of AI in chemistry, the importance of scientific collaboration, and some of the wider questions around responsible innovation and dual-use risk as generative drug discovery continues to develop.

2. Episode 255 - Jason Goodson - COO at PleoPharma

   2 november 2026 · 20 min

   Afspelen
   n this episode of The BioHub, we welcome Jason Goodson, Chief Operating Officer at PleoPharma, a clinical-stage biotechnology company developing innovative treatments for cannabis use disorder and cannabis withdrawal syndrome. Lees meer

   With millions of Americans affected by cannabis use disorder and no FDA-approved medications specifically targeting cannabis withdrawal, PleoPharma is working to address a significant unmet need through its lead candidate, PP-01, now in pivotal Phase 3 development.

   Jason shares insights into the growing market for addiction therapeutics, the clinical and commercial potential of PP-01, and the challenges of bringing a first-in-class treatment to market.

   We also explore the strategic decisions behind scaling a clinical-stage biotech, from financing and partnerships to commercial readiness, leadership, and building the right team for future growth.

3. Episode 254 - Erick Lucera (CFO) & Vikram Ranade (CBO) at Dyne Therapeutics

   29 oktober 2026 · 29 min

   Afspelen
   Today, we’re joined by Erick Lucera, Chief Financial Officer, and Vikram Ranade, Chief Business Officer at Dyne Therapeutics. We’ll be discussing their individual journeys through biotech, what attracted them to Dyne, and the company’s mission to develop transformative treatments for people living with genetically driven neuromuscular diseases. We’ll also explore the strategy behind building a biotech towards commercialisation, the financial and business development challenges involved, and their perspectives on the wider biotech landscape. Lees meer

4. Episode 253 - John Yu CEO at Kairos Pharma

   26 oktober 2026 · 16 min

   Afspelen
   In this episode of The BioHub Podcast, Ben is joined by Dr. John Yu, CEO and Chairman of Kairos Pharma, a clinical-stage biotechnology company developing innovative therapies to overcome drug resistance and immune suppression in cancer. Lees meer

   Dr. Yu brings a unique perspective from his extensive career in neurosurgery, oncology, immunology, and biotechnology entrepreneurship. Together, they explore his journey from academic medicine into biotech leadership, the science behind Kairos Pharma's approach to tackling cancer drug resistance, and the development of its lead candidate, ENV105, which targets CD105 to potentially restore sensitivity to existing cancer treatments.

   The conversation also examines the challenges of translating academic discoveries into clinical therapies, building and financing an emerging biotechnology company, and the opportunities ahead for improving cancer treatment outcomes.

   An insightful discussion on scientific innovation, entrepreneurship, and the journey from breakthrough research to meaningful patient impact.

5. Episode 252 - Sam Reich - CEO at SAB Bio

   26 oktober 2026 · 25 min

   Afspelen
   In this episode of The BioHub by Avetix, I’m joined by Sam Reich, CEO of SAB BIO. Lees meer

   Sam shares his unconventional journey from leaving his PhD to build his first biotech, through founding and selling companies, working with influential industry figures like Phil Frost, and eventually leading Big Cypress Acquisition Corp.

   We discuss how that journey brought him to SAB BIO, why the company became the right opportunity, the challenges behind its strategic pivot towards type 1 diabetes, and what it takes to keep adapting when the path of a biotech changes.

   We also explore the lessons Sam has learned from building, financing and leading companies across multiple stages, and what comes next for SAB as it works to develop a disease-modifying treatment for type 1 diabetes.

6. Episode 250 - Dr. Garry Pairaudeau, Co-Founder CEO & Dr. Anthony Bradley, Co-Founder CSO of Dalton Tx

   22 oktober 2026 · 30 min

   Afspelen
   In this episode of The BioHub, Amber is joined by Dr. Garry Pairaudeau, Co-Founder and CEO, and Dr. Anthony Bradley, Co-Founder and CSO of Dalton Tx. Lees meer

   Having previously worked together at Exscientia, Garry and Anthony went on to co-found Dalton Tx. bringing together AI, scientific expertise and software engineering to help accelerate drug discovery.

   We explore their journey the challenges of translating advances in AI into meaningful scientific impact, and the importance of separating genuine innovation from industry hype.

   We also discuss the evolving role of AI in drug discovery, building a science-driven company, and what the future could hold for AI-enabled therapeutics.

7. Why Biotech Keeps Reinventing the Wheel | Greg Crescenzi, Addgene

   21 oktober 2026 · 18 min

   Afspelen
   Why spend months recreating research tools that another lab has already built? Lees meer

   In this episode of The BioHub, we’re joined by Greg Crescenzi from Addgene to discuss how sharing scientific materials can reduce duplicated work, save researchers time and help biotech discoveries move faster.

   From plasmids and CRISPR tools to viral vectors and antibodies, Greg explains how Addgene helps scientists build on existing research—and why improving access between academia and industry is the next challenge.

   We cover:

   • The frustration that sparked Addgene’s founding
   • How sharing research tools helped CRISPR reach thousands of organisations
   • The barriers between academic research and commercial biotech
   • Partnerships supporting better sequencing and new research tools
   • Why unsuccessful experiments contain information worth sharing
   • Where AI and Addgene’s research data could create new opportunities

   Subscribe to The BioHub for more conversations with the people advancing biotech.

   #Biotech #Addgene #CRISPR #BioHub

8. Episode 248- Marshall Fordyce - Founder & CEO of Vera Therapeutics

   20 oktober 2026 · 27 min

   Afspelen
   In this episode of The BioHub by Avetix, I’m joined by Marshall Fordyce, Founder and CEO of Vera Therapeutics. Lees meer

   Marshall shares his journey from medicine and HIV drug development at Gilead to founding Vera, and how that experience shaped his belief in the power of building medicines that can genuinely change the course of disease.

   We discuss what patient-centricity looks like in practice, the thinking behind Vera’s Phase III strategy, and the company’s transition from development-stage biotech into commercial launch. Marshall also shares his framework for building biotech companies, why people and capital discipline matter just as much as the science, and what comes next for Vera as it continues the US launch of Trutacna.

9. Episode 247 - Chris Moxham Founder & CEO and Clayton Mellina CTO of Transcripta Bio

   19 oktober 2026 · 25 min

   Afspelen
   In this episode of The BioHub, Amber is joined by Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, and Clayton Mellina, CTO, to explore how transcriptomics and AI are opening up new possibilities in drug discovery. Lees meer

   Chris and Clayton explain how Transcripta connects the changes disease causes in cells with the effects of potential treatments. They discuss combining phenotypic screening with target-based discovery, finding new uses for existing medicines, and reducing risk earlier in development.

   The conversation covers their work in genetically defined autism spectrum disorders and Huntington’s disease, their collaboration with Mayo Clinic, and how AI agents could help small scientific teams explore thousands of hypotheses.

10. Episode 246 - Neil Warma - CEO, ProMIS Neurosciences

    19 oktober 2026 · 39 min

    Afspelen
    In this episode of The BioHub Podcast by Avetix, we welcome Neil Warma, President and CEO of ProMIS Neurosciences, a clinical-stage biotechnology company developing next-generation therapies targeting toxic, misfolded proteins associated with neurodegenerative diseases. Lees meer

    Neil shares insights from his extensive career building and leading biotechnology companies, before exploring ProMIS' differentiated approach to treating Alzheimer's disease. We discuss PMN310, an antibody designed to selectively target toxic amyloid-beta oligomers while avoiding plaque, its ongoing Phase 1b PRECISE-AD clinical trial, and the potential to improve both efficacy and safety in Alzheimer's treatment.

    The conversation also explores ProMIS' broader ambitions across ALS and Parkinson's disease, upcoming clinical milestones, and Neil's perspective on leadership, financing, and building successful biotechnology companies.

Alle 282 afleveringen →